301 related articles for article (PubMed ID: 19731103)
1. Pharmacology, pharmacogenetics, and pharmacoepidemiology: three ps of individualized therapy.
Dawood S
Cancer Invest; 2009 Oct; 27(8):809-15. PubMed ID: 19731103
[No Abstract] [Full Text] [Related]
2. Cancer pharmacogenetics.
Marsh S
Methods Mol Biol; 2008; 448():437-46. PubMed ID: 18370241
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of genetic polymorphisms on stomach cancer drug therapy.
Toffoli G; Cecchin E
Pharmacogenomics J; 2007 Apr; 7(2):76-80. PubMed ID: 16801937
[No Abstract] [Full Text] [Related]
4. Genetic profiling can predict chemotherapy side effects and treatment response.
Expert Rev Mol Diagn; 2003 Jul; 3(4):406-7. PubMed ID: 12877380
[No Abstract] [Full Text] [Related]
5. Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy.
Andreopoulou E; Hortobagyi GN
J Clin Oncol; 2008 Aug; 26(22):3660-2. PubMed ID: 18669447
[No Abstract] [Full Text] [Related]
6. NCI launches an innovative design for a breast cancer clinical trial.
Whitworth A
J Natl Cancer Inst; 2006 Sep; 98(17):1178-9. PubMed ID: 16954467
[No Abstract] [Full Text] [Related]
7. Translational research in breast cancer.
Chu QD; Holm N; Byrnes K; Li BD
Surg Oncol Clin N Am; 2008 Apr; 17(2):421-38, x. PubMed ID: 18375360
[TBL] [Abstract][Full Text] [Related]
8. CYP450 pharmacogenetics for personalizing cancer therapy.
van Schaik RH
Drug Resist Updat; 2008 Jun; 11(3):77-98. PubMed ID: 18486526
[TBL] [Abstract][Full Text] [Related]
9. Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update).
Grunfeld E; Dhesy-Thind S; Levine M;
CMAJ; 2005 May; 172(10):1319-20. PubMed ID: 15883407
[No Abstract] [Full Text] [Related]
10. [Individualized anticancer therapies: which regulatory guidelines?].
Bedairia N; Marty M
Bull Cancer; 2008 Oct; 95(10):985-8. PubMed ID: 19004730
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy and pharmacogenomic programs.
Iqbal S; Lenz HJ
Cancer; 2003 Apr; 97(8 Suppl):2076-82. PubMed ID: 12673699
[TBL] [Abstract][Full Text] [Related]
12. Gender differences in the dihydropyrimidine dehydrogenase expression may contribute to higher toxicity in women treated with 5-fluorouracil therapy.
Altundag O; Altundag K; Silay K; Turen S
Med Hypotheses; 2005; 65(6):1196. PubMed ID: 15951130
[No Abstract] [Full Text] [Related]
13. [High-dosage treatment of breast cancer - against].
Hossfeld DK
Dtsch Med Wochenschr; 2001 Sep; 126(39):1092. PubMed ID: 11602919
[No Abstract] [Full Text] [Related]
14. Personalized systemic treatment for breast cancer patients: is it a reality?
Shimizu C; Fujiwara Y
Breast Cancer; 2008; 15(2):141-4. PubMed ID: 18274835
[TBL] [Abstract][Full Text] [Related]
15. Current overview of pharmacogenetics.
McLeod HL
Clin Adv Hematol Oncol; 2004 Apr; 2(4):205-7. PubMed ID: 16163181
[No Abstract] [Full Text] [Related]
16. Template for toxicants: gene expression varies by cell type.
Barrett JR
Environ Health Perspect; 2004 Nov; 112(16):A944. PubMed ID: 15598609
[No Abstract] [Full Text] [Related]
17. Give us clear, not convoluted, clinical practice guidelines.
Sehmer J
CMAJ; 2001 Nov; 165(11):1468-9. PubMed ID: 11762568
[No Abstract] [Full Text] [Related]
18. How not to treat cancer.
Schilsky RL
Lancet Oncol; 2008 Jun; 9(6):504-5. PubMed ID: 18510981
[No Abstract] [Full Text] [Related]
19. Infusion of pharmacogenetics into cancer care.
Prows CA
Semin Oncol Nurs; 2011 Feb; 27(1):45-53. PubMed ID: 21255712
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacogenetics in fluoropyrimidine chemotherapy].
Ichikawa W; Sasaki Y
Gan To Kagaku Ryoho; 2008 Feb; 35(2):178-81. PubMed ID: 18281752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
